Vir Biotechnology to Present at H.C. Wainwright 22nd Annual Global Investment Conference
A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there following the presentation for 30 days.
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting hepatitis B virus, influenza A, SARS-CoV-2, human immunodeficiency virus and tuberculosis. For more information, please visit www.vir.bio.
Vir Biotechnology, Inc.Investors Neera Ravindran, MD VP, Head of Investor Relations & Strategic Communicationsnravindran@vir.bio +1-415-506-5256 Media Julie Normart W2O Groupjnormart@w2ogroup.com +1-559-974-3245
Source: Vir Biotechnology, Inc.